Leucine alpha-ketoglutarate

Leucine Alpha-Ketoglutarate (Leu-AKG): A Comprehensive Reference

1. Identity, Chemical Characterization, and Natural Sources

Leucine alpha-ketoglutarate (Leu-AKG) is a compound that combines the essential branched-chain amino acid leucine with alpha-ketoglutarate, a key intermediate in the Krebs cycle. In the dietary supplement literature, this combination is sometimes sold as a single salt or conjugate, though it is more commonly encountered as a blended formulation where each component is included separately.

Leucine (L-Leucine) is an essential branched-chain amino acid (BCAA) with the chemical formula C₆H₁₃NO₂ and the IUPAC name 2-amino-4-methylpentanoic acid. It cannot be synthesized endogenously in humans and must be obtained from the diet. It is abundant in protein-rich foods, including meat, dairy, eggs, legumes, and soy proteins.

Alpha-Ketoglutarate (AKG), also known as 2-oxoglutaric acid or 2-oxopentanedioic acid, is an endogenous dicarboxylic alpha-keto acid. AKG is a crucial intermediate in the tricarboxylic acid (TCA) cycle and is also a product of glutamine deamination (glutaminolysis). AKG is a weak acid containing two carboxyl groups and a ketone group. As an endogenous metabolite, AKG is not obtained directly from food but is produced intracellularly. Notably, AKG levels decrease in aging; in fact, there is a reported approximately 10-fold decrease in AKG between ages 40 and 80.

The metabolic relationship between these two molecules is fundamental. Cytosolic branched-chain-amino-acid aminotransferase (BCAT1) catalyzes the reversible reactions of leucine, isoleucine, or valine with alpha-ketoglutarate (2-oxoglutarate) to form alpha-ketoisocaproate, alpha-keto-beta-methylvalerate, or a-ketoisovalerate, respectively, and glutamate. This biochemical coupling — wherein leucine and AKG are co-substrates in transamination — is the mechanistic basis for combining them.

Common Forms and Preparations

• Free-acid combination: Leucine and alpha-ketoglutaric acid co-formulated in powder or capsule form at various ratios.
• Calcium alpha-ketoglutarate (Ca-AKG): Calcium alpha-ketoglutarate (Ca-AKG) is a naturally occurring salt of alpha-ketoglutarate, a key metabolite in cellular energy metabolism. This salt form has been described as more stable for oral supplementation.
• Arginine alpha-ketoglutarate (AAKG): Products that contain this ingredient usually list it as L-arginine alpha-ketoglutarate (AAKG) on their labels, a form more commonly associated with the sports nutrition sector.
• Ornithine alpha-ketoglutarate (OKG): A related salt (ornithine paired with AKG) that has an extensive clinical research record, particularly in the context of burn patients and surgical recovery (discussed further in the clinical evidence section).
• Sustained-release oral tablets: Used in clinical longevity trials, typically delivering 1 g of Ca-AKG per day.

2. Traditional and Historical Use

Neither leucine nor alpha-ketoglutarate, in their isolated or combined forms, has a documented history of use in traditional herbal or botanical medicine systems, such as Ayurveda, Traditional Chinese Medicine, or European folk herbalism. Both are endogenous metabolites identified through 20th-century biochemistry.

The earliest medicinal use of alpha-ketoglutarate arose in modern clinical nutrition, specifically in the context of parenteral and enteral support for critically ill patients. A few studies published in the 1980s and 1990s in humans suggested the potential benefits of AKG in muscle growth, wound healing, and in promoting faster recovery after surgery. Research published in the Lancet in 1990 by Wernerman, Hammarqvist, and Vinnars examined alpha-ketoglutarate in the context of postoperative muscle catabolism — among the earliest clinical applications of the molecule in humans.

The use of leucine as a nutritional therapy has a somewhat longer, though still modern, clinical history. Use of AKG or calcium-AKG as dietary supplements has mainly been studied on hospitalized adult humans, who are well nourished and have a normal functional metabolism. The concept of using alpha-keto acid supplements in renal disease also has roots in clinical nephrology of the 1970s–1990s, where low-protein diets supplemented with keto-analogues of essential amino acids were employed to reduce the nitrogen load in patients with chronic kidney failure.

The popularity of isolated leucine supplementation in sports nutrition grew substantially from the 1990s onward, driven by research elucidating its unique mTOR-activating properties. The combination of leucine with AKG as a distinct supplement preparation is an innovation of contemporary functional nutrition, with no traditional cultural context.

3. Key Constituents and Established Mechanisms of Action

3.1 Leucine: Mechanisms

Recent research has uncovered the mechanisms underlying leucine's anabolic effects on muscle and other tissues, including its ability to stimulate protein synthesis by activating the mTORC1 signaling pathway.

The anabolic mechanism is performed by the activation of the mRNA translational machinery through the mammalian target of rapamycin (mTOR), a protein with a molecular weight of around 290 kD, in an insulin-dependent or independent manner. Leucine treatment enhances the phosphorylation of mTOR, and its activation up-regulates protein translation through the phosphorylation of the eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase (S6K), leading to cell growth and proliferation.

Unlike insulin and IGF-1, leucine has a direct effect at an intracellular locus modulating protein signaling pathways, and does not appear to require the mediation of a cell membrane receptor, acting efficiently in protein synthesis.

Leucine stimulates mTORC1 activation by bringing the protein to the surface of lysosomes, where growth factors and other amino acids may stimulate it. Multiple downstream targets of mTORC1 are phosphorylated, which stimulates translation initiation and ribosome biogenesis.

In addition to its role in protein synthesis, leucine also plays a role in the oxidation of fatty acids in skeletal muscle. Leucine stimulates fatty acid oxidation by activating the AMP-activated protein kinase (AMPK) pathway.

α-Ketoisocaproic acid (α-KIC), also known as 4-methyl-2-oxovaleric acid, is a metabolic intermediate in the pathway for L-leucine. Leucine is an essential amino acid, and its degradation is critical for many biological duties. α-KIC is produced in one of the first steps of the pathway by branched-chain amino acid aminotransferase, by transferring the amine on L-leucine onto alpha-ketoglutarate and replacing that amine with a ketone. This reaction underscores the direct biochemical interdependence of leucine and AKG.

3.2 Alpha-Ketoglutarate: Mechanisms

As a metabolite, AKG is an antioxidant, regulates nitrogen and ammonia balance, as well as epigenetic and immune processes. AKG is also a substrate for Ten-Eleven Translocation (TET) methylcytosine dioxygenases, which contribute to DNA demethylation.

AKG is a nitrogen scavenger and a source of glutamate and glutamine that stimulates protein synthesis and inhibits protein degradation in muscles. AKG as a precursor of glutamate and glutamine is a central metabolic fuel for cells of the gastrointestinal tract as well. AKG can decrease protein catabolism and increase protein synthesis to enhance bone tissue formation in the skeletal muscles and can be used in clinical applications.

AKG can influence bone strength and density and inhibit carcinogenesis induced by oncometabolites or hypoxia by activating enzymes from the 2-OGDD family (2-oxoglutarate-dependent dioxygenases). Their action involves epigenetic regulation such as histone and DNA demethylation carried out by KDM 2–7 (Jumonji C domain-containing lysine demethylases) and TET 1–3 (10–11 translocation hydroxylases), respectively, and non-epigenetic regulation, which includes activation of prolyl hydroxylases: P4H (prolyl 4-hydroxylase) involved in type I collagen biosynthesis and PHD2 (prolyl hydroxylase domain-containing protein 2) responsible for hydroxylation and thus inactivation of HIF-1α.

Alpha-ketoglutarate produced by glutamate dehydrogenase plays a critical role in mTORC1 activation. Although there was no observed difference in GDH activity, the amount of alpha-ketoglutarate in gastrocnemius muscle may increase due to increased availability of glutamate, which in turn could affect mTORC1 activation.

Mitochondrial function decreases with age, which could contribute to the overall decrease in levels of AKG.

3.3 Synergy of the Combination

Leucine has long been used for its ability to stimulate muscle protein synthesis, prevent muscle breakdown, and support recovery. Alpha-ketoglutarate, on the other hand, has been valued for its role in energy production and its capacity to serve as a nitrogen transporter, which is crucial for cellular metabolism and detoxification. By providing both the anabolic signal (leucine → mTOR activation) and a key Krebs cycle intermediate that supports energy production and nitrogen scavenging (AKG), the combination is theorized to address multiple aspects of muscle metabolism simultaneously. However, direct head-to-head clinical trials comparing the Leu-AKG combination to either component alone are limited in the peer-reviewed literature, and the degree of functional synergy in humans remains to be rigorously established.

4. Scientific Evidence by Area of Use

4.1 Skeletal Muscle Mass, Strength, and Sarcopenia

Evidence for leucine component (human/clinical):

A placebo-controlled, randomized, double-blind trial enrolled fifty participants aged 65 and over and randomized them to a parallel group intervention of 13 weeks' duration with a daily intake of leucine (6 g/day) or placebo. Administration of leucine was well-tolerated and significantly improved some criteria of sarcopenia in elderly individuals, such as functional performance measured by walking time (p = 0.011), and improved lean mass index. For respiratory muscle function, the leucine-treated group improved significantly (p = 0.026) in maximum static expiratory force compared to the placebo. No significant effects on functional impairment, cognitive function, nutritional assessment, or inflammatory cytokines IL-6 and TNF-alpha were observed after leucine administration compared to placebo.

Studies suggested that L-leucine supplementation was able to enhance muscle protein synthesis in the elderly. A systematic review and meta-analysis published in Frontiers in Nutrition (2022) pooled data from 17 randomized controlled trials; some RCTs indicated that leucine could improve clinical indicators of sarcopenia in the elderly, including functional performance, and improve bone mineral-free lean tissue mass.

In neonatal pig studies, leucine infusion increased the rate of protein synthesis and S6K1 and 4E-BP1 phosphorylation in gastrocnemius and masseter muscles (p < 0.05), but not in the liver. The leucine-induced stimulation of protein synthesis and S6K1 and 4E-BP1 phosphorylation were completely blocked by rapamycin, suggesting that leucine action is by an mTORC1-dependent mechanism. This neonatal porcine model is a commonly used preclinical surrogate for protein metabolism research, though direct translation to adult human physiology has limitations.

Evidence for AKG component (preclinical and limited clinical):

Although the beneficial effects of AKG on skeletal muscle mass and function are evident, there are still many gaps in current research. Most studies come from pre-clinical research or small-scale clinical trials, and the potential mechanism by which AKG functions remains unclear.

Evidence strength assessment: For leucine as an isolated intervention in sarcopenia, the evidence is moderate — supported by multiple RCTs with consistent directional effects, though effect sizes are modest and variability across studies exists. For AKG specifically in skeletal muscle outcomes in humans, evidence remains preliminary. No large RCT has yet tested the Leu-AKG combination as a single formulation against placebo for sarcopenia endpoints.

4.2 Postoperative and Critical Care Recovery

In clinical studies on septic, traumatic, or surgical patients, AKG has been found to display beneficial effects by improving body weight gain and nitrogen balance.

A study by Wiren and Permert published in Nutrition (2002) enrolled patients undergoing elective abdominal surgery: the aim was to evaluate the feasibility of alpha-ketoglutarate enrichment of enteral feeding and its effect on protein metabolism after major surgery. Patients were randomly allocated to receive a standard whole-protein-based enteral nutrition solution (n = 9) or an isonitrogenous, isocaloric solution enriched with alpha-ketoglutarate (n = 11) for 5 days postoperatively. There were no significant differences in nitrogen balance, excretion of 3-methylhistidine, or clinical outcome between groups. Enrichment of a whole-protein-based formula with alpha-ketoglutarate did not improve protein metabolism or decrease muscle catabolism after major abdominal surgery. This null finding is an important counterpoint to more positive earlier work.

Earlier research using ornithine alpha-ketoglutarate (OKG — a structurally distinct but related salt) in burn patients showed different results. In a prospective, randomized, double-blind study, 60 patients who had undergone severe burns (20–60% of body surface area) received either ornithine alpha-ketoglutarate (20 g/day) or an isocaloric placebo for 21 days. In the OKG group, nitrogen balance reached positive values at day 5 and stabilized at higher levels versus controls (p < 0.05 or less from day 3 to day 21), resulting in a strongly positive cumulated nitrogen balance at day 21 (OKG group: +127 ± 13 g nitrogen; control group: −63 ± 18 g nitrogen).

Similarly, a randomized controlled trial with burn patients by Cynober and colleagues found that 54 burn patients (total burn surface area: 20–50%) were included and assigned to receive either a supplement of OKG (10, 20, or 30 g/d) as bolus or continuous infusion, or a continuous infusion of an isonitrogenous amount of a soy protein mixture. OKG administration significantly improved nitrogen balance and reduced 3-methylhistidine and hydroxyproline urinary elimination. This was associated with a gradual rise in plasma glutamine over time.

Evidence strength assessment: The clinical evidence base for pure alpha-ketoglutarate in surgical recovery is mixed — some trials show nitrogen balance benefits while others show no significant effect. The OKG literature (ornithine + AKG salt) is more consistently positive in critically ill and burn patients, but OKG is not identical to the Leu-AKG combination. Results from OKG studies are not directly transferable to Leu-AKG.

4.3 Renal Disease and Amino Acid Metabolism

In hemodialysis patients, free amino acids and alpha-ketoacids in plasma were determined by fluorescence HPLC to assess the effect of alpha-ketoglutarate administration in combination with the phosphate binder calcium carbonate on amino acid metabolism. During one year of therapy, in parallel to inorganic phosphate, urea in plasma decreased significantly, while histidine, arginine, and proline as well as branched-chain alpha-ketoacids, in particular alpha-ketoisocaproate, a regulator of protein metabolism, increased. Thus, administration of alpha-ketoglutarate with calcium carbonate effectively improves amino acid metabolism in hemodialysis patients as it decreases hyperphosphatemia.

Administration of calcium-AKG in chronic renal failure patients undergoing hemodialysis improved kidney functions, including increased plasma concentrations of arginine, proline, and histidine, as well as decreased inorganic phosphate and urea.

Evidence strength assessment: The evidence for AKG in hemodialysis patients improving amino acid metabolism markers is limited but positive, derived from small-scale studies conducted primarily in the 1990s. Larger, prospective RCTs are lacking.

4.4 Bone Health and Osteoporosis

In the context of osteoporosis treatment, research conducted on postmenopausal women with this condition demonstrated that the administration of daily oral calcium alpha-ketoglutarate (6 g α-KG over a duration of six months) resulted in a 1.6% increase in bone density relative to baseline measurements. The underlying mechanism involves the regulation of epigenetic processes by alpha-KG, which aligns with the regulatory effects of alpha-KG on osteoblast activity.

Preclinical mechanistic work has clarified how AKG may exert bone-protective effects. Administration of alpha-ketoglutarate to mice reduces age-related bone loss by ameliorating senescence of bone-marrow-derived mesenchymal stem cells. At the epigenetic level, data show that αKG relieves the overall burden of H3K9me3 and H3K27me3, with little effects on levels of H3K4me3, H3K9ac, and H3K27ac. H3K9me3 and H3K27me3 are two critical histone modifications that are closely associated with cell senescence and organismal aging, and age-associated osteoporosis.

Regarding osteoclast regulation, osteoclastogenesis was negatively regulated by αKG in vitro and in vivo (C57BL/6 mouse). RANKL-induced ROS production was inhibited by αKG. Notably, αKG plays an epigenetic co-factor role at the Slc7a11 promoter by demethylating repressive histone H3K9 methylation and simultaneously increasing the nuclear factor erythroid 2-related factor (Nrf2) binding.

Evidence strength assessment: Preclinical evidence (mouse models, cell culture) for AKG's bone-protective effects is mechanistically coherent. Human evidence is limited to one study reporting a modest bone density increase in postmenopausal women. This area requires larger, adequately powered RCTs before clinical conclusions can be drawn.

4.5 Aging, Longevity, and Epigenetics

AKG is an endogenous intermediary metabolite in the Krebs cycle whose levels naturally decline during aging.

In a study sponsored by Ponce de Leon Health and performed at the Buck Institute for Research on Aging, the effect of alpha-ketoglutarate (delivered in the form of a calcium salt — CaAKG) on healthspan and lifespan in C57BL/6 mice was reported. The authors showed that in the mice, AKG reduced frailty and enhanced longevity, indicating a compression of morbidity.

An early human observational study using the Rejuvant® formulation (sustained-release CaAKG + vitamins) examined the cross-sectional and longitudinal association between the epigenetic clock, health status, physical fitness, and the effects of taking supplementation on human biological aging; 42 self-reported healthy individuals who had taken AKG supplementation for a period of 4 to 10 months were followed. Individuals showed an average decrease in biological aging of 8 years (p-value = 6.538×10⁻¹²). This study's limitations include its small size, lack of a concurrent placebo group, self-reported health status, and the use of a multi-ingredient formulation, meaning the effects cannot be attributed to AKG alone.

One of the most important studies currently investigating AKG is the ABLE study (Alpha-Ketoglutarate Supplementation and BiologicaL agE in middle-aged adults), a randomized, double-blind, placebo-controlled clinical trial designed to test whether daily supplementation with calcium AKG can reduce biological age in humans. The study includes around 120 healthy adults between the ages of 40 and 60, all of whom have a biological age higher than their chronological age. Participants receive either 1 gram of sustained-release calcium AKG or a placebo for six months, followed by an additional three months of follow-up.

So far there are no recently published studies demonstrating the role of AKG in treating aging and age-related diseases; hence, further clinical studies are required to better understand the role of AKG in humans.

Evidence strength assessment: The evidence for AKG as a pro-longevity compound in humans is preliminary and still emerging. Preclinical evidence (C. elegans, mice) is suggestive. The sole human cohort study (Rejuvant®) has significant methodological limitations. The ABLE RCT represents the most rigorous ongoing test of this hypothesis.

4.6 Cardiovascular and Renal Intraoperative Effects

Infusion of alpha-KG enhances renal blood flow early after coronary surgical procedures in patients with normal renal function. The mechanism is unclear, but could be associated with primarily metabolic effects, and may potentially convey a beneficial effect for renal function. This research was conducted in the context of cardiac surgery and IV administration, not oral supplementation.

4.7 Metabolic Health and Insulin Sensitivity

Leucine has been shown to benefit lipid metabolism and insulin sensitivity, making it a promising strategy for preventing and treating metabolic diseases, including type 2 diabetes and obesity. However, the evidence in human intervention studies is not uniform. Leucine supplementation might exert positive systemic effects in conditions characterized by disturbances in glucose homeostasis, such as high-fat-diet-induced insulin resistance, but the effects are controversial. For example, Zhang and coworkers found increases in glucose metabolism of leucine-supplemented mice, whereas Lynch and coworkers did not observe improvements or decreases in glucose homeostasis.

Evidence strength assessment: Evidence for metabolic effects of leucine (and of AKG) on glucose and lipid metabolism is largely preclinical and inconsistent. Human RCT evidence is insufficient to draw firm conclusions.

5. Body Systems and Health Areas of Association

• Musculoskeletal system: Leucine's mTOR-mediated anabolic effects on skeletal muscle protein synthesis are the best-characterized mechanism in this field. AKG contributes via nitrogen scavenging, glutamine provision, and satellite cell stimulation. AKG supports muscle recovery by stimulating muscle satellite cells (MuSCs) and macrophage polarization, aiding muscle repair and reducing fibrosis.
• Skeletal/bone system: AKG has been shown to inhibit osteoclastogenesis and reduce senescence of mesenchymal stem cells, supporting bone density preservation via epigenetic mechanisms.
• Metabolic/energy systems: AKG is an intermediate of the Krebs cycle, which is involved in various metabolic and cellular pathways as a signalling molecule, energy source, and precursor of amino acid synthesis.
• Renal system: AKG has been studied in hemodialysis patients for its effect on amino acid metabolism and hyperphosphatemia.
• Immune/epigenetic regulation: As an antioxidant, AKG interferes in nitrogen and ammonia balance and affects epigenetic and immune regulation. These pleiotropic functions of AKG suggest it may also extend human healthspan.
• Aging biology: AKG's role as a cofactor for TET and Jumonji C-domain enzymes places it at the intersection of metabolism and epigenetic aging clocks.
• Cardiovascular system: Intravenous AKG has been studied in cardiac surgery contexts for renal protection and myocardial metabolic support.

6. Dosage Forms and Dosages Reported in Studies

No single universally established therapeutic dose for the Leu-AKG combination has been defined in peer-reviewed literature. Dosages for each component as studied independently are as follows:

Leucine

• Participants in the sarcopenia RCT received a daily intake of leucine of 6 g/day for 13 weeks.
• In one trial, healthy elderly men were supplemented with 2.5 g of leucine at each main meal for a period of 3 months without any reported adverse effects.
• In another report, no adverse effects were associated with repeated oral administration of up to 60 g/day of BCAAs (providing 24 g/day of leucine) in patients with bipolar disorder.

Alpha-Ketoglutarate

• Daily oral calcium alpha-ketoglutarate at 6 g of α-KG over a duration of six months was used in the postmenopausal osteoporosis study.
• In the ABLE longevity trial, participants receive either 1 gram of sustained-release calcium AKG or a placebo for six months.
• For chronic kidney disease, studied doses include 1.187 g of alpha-ketoglutarate plus 0.813 g of calcium carbonate three times weekly; also approximately 4.5 g of calcium alpha-ketoglutarate has been used daily for 3 years.
• In the severe burns RCT, ornithine alpha-ketoglutarate was used at 20 g/day for 21 days.
• In the postoperative enteral nutrition study, patients received an AKG-enriched solution for 5 days postoperatively.
• A review reported that AKG's safety record is strong, with doses up to 6 grams per day generally well tolerated.

7. Safety Considerations and Interactions

7.1 Leucine Safety

No consistent evidence of toxicity has been linked to leucine supplements. In healthy subjects, no adverse events have been reported by subjects consuming oral leucine for a 6-week period.

The body of evidence on oral administration of leucine in humans indicates that it can be consumed in considerable amounts without adverse effects. There are no dose-limiting toxicities known with oral leucine. There is also no defined maximum tolerated dose and no recommended phase II dose reported for this supplement.

Excessive intake of L-leucine (greater than 750 mg/kg body weight) may result in hypoglycemia. Leucine, when consumed as a dietary supplement at high doses (>500 mg/kg/day), has been associated with an increase in blood ammonia levels. While not reported in human beings, animal models suggest that very high doses of L-leucine (in rodent models at 15 g/kg) may lead to pellagra-like symptoms due to disruption of tryptophan metabolism.

7.2 Potential Drug Interactions Involving Leucine

L-leucine also has a synergistic effect on the action of phosphodiesterase 5 (PDE5) inhibitors and may lead to interaction with medications such as sildenafil. The potential for synergism between leucine, metformin, and sildenafil exists. The combination may magnify the hypoglycemic effects of metformin.

7.3 Alpha-Ketoglutarate Safety

Alpha-ketoglutarate is a chemical that naturally occurs in the body, where it plays an important role in many processes. In addition to working as an antioxidant, it reduces inflammation and helps cells make energy. The body also uses alpha-ketoglutarate to make amino acids, which are the building blocks of protein.

AKG is generally regarded as well-tolerated at supplemental doses. High doses may cause mild gastrointestinal discomfort in some individuals. No serious adverse events have been consistently documented in the peer-reviewed clinical literature at doses up to 6 g/day.

7.4 Formulation-Specific Safety Concerns

The salt form of AKG selected for supplementation carries distinct considerations. Some supplements may contain alpha-ketoglutarate combined with calcium, and products that contain this ingredient usually list it as calcium alpha-ketoglutarate (Ca-AKG) on their labels. Calcium supplements might increase the risk of kidney stones, especially if the individual has had kidney stones before. If someone has a history of kidney stones, they should speak with their health care provider before taking Ca-AKG.

For arginine alpha-ketoglutarate (AAKG), a separate concern arises from the arginine component: the main ingredient in AAKG products is arginine alpha-ketoglutarate, which is claimed to increase nitric oxide (NO) production by supplying the precursor L-arginine. Reported symptoms could be due to vasodilation from increased levels of NO, though other etiologies cannot be excluded.

The FDA has not reviewed alpha-ketoglutarate for safety and effectiveness as a dietary supplement in any formal product-specific approval or monograph process.

7.5 Special Populations

Clinical trials on leucine and AKG supplementation have generally excluded pregnant or breastfeeding individuals, children, and those with severe renal or hepatic impairment. No peer-reviewed evidence characterizes safety in these groups for the Leu-AKG combination specifically.

8. State of the Evidence: Summary Appraisal

The individual components of Leu-AKG have distinct and reasonably well-characterized mechanistic profiles. Leucine's activation of the mTORC1 pathway is one of the most robustly established mechanisms in amino acid biology, supported by both preclinical and human data. AKG's roles as a Krebs cycle intermediate, nitrogen transporter, and epigenetic cofactor are also well-established biochemically. Clinical evidence for leucine in sarcopenia is moderate in quality, with multiple small-to-moderate RCTs showing modest but directionally consistent benefits in elderly populations.

For AKG in aging, bone health, and surgical recovery, the human evidence base ranges from preliminary to mixed. The most methodologically rigorous ongoing research — the ABLE trial — has not yet reported final results. Evidence for the specific Leu-AKG combination as a unified preparation is sparse in the primary literature; most available data pertain to each component studied independently or in other pairings (such as OKG or Ca-AKG). Claims about synergistic effects of the Leu-AKG combination in humans cannot yet be adequately substantiated by the available clinical evidence.

References

• Cieślak M, et al. Alpha-Ketoglutarate: Physiological Functions and Applications. Biomol Ther (Seoul). 2016;24(1):1–10. PMC4703346
• Żołkiewicz J, et al. Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. Arch Immunol Ther Exp (Warsz). 2021;69(4):18. PMC5274648
• Ispoglou T, et al. Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial. Nutrients. 2020;12(7):1999. PMC7230494
• Chen Y, et al. The Effect of Leucine Supplementation on Sarcopenia-Related Measures in Older Adults: A Systematic Review and Meta-Analysis of 17 Randomized Controlled Trials. Front Nutr. 2022;9:929891
• Churchward-Venne TA, et al. Leucine-Enriched Nutrients and the Regulation of mTOR Signalling and Human Skeletal Muscle Protein Synthesis. Amino Acids. 2012;45(5):1553–1567. PMC5096790
• Research progress in the role and mechanism of Leucine in regulating animal growth and development. Front Physiol. 2023;14:1252089
• Research progress in the role and mechanism of Leucine in regulating animal growth and development. Front Physiol. 2023. PMC10691278
• He L, et al. Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways. Sci Rep. 2016 (Note: this article was subsequently retracted). PMC4881026
• Nishimura M, et al. Co-ingestion of glutamine and leucine synergistically promotes mTORC1 activation. Sci Rep. 2022;12:16289
• Sandalova E, et al. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE) — intervention study protocol. Aging Clin Exp Res. 2023;35:1989–1998. PMC10643463
• Demidenko O, et al. Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging. Aging (Albany NY). 2021;13(22):24194. PMC8660611
• Maier AB, et al. Alpha-Ketoglutarate dietary supplementation to improve health in humans. Nutr Healthy Aging. 2022;6(4):169–178. PubMed 34952764
• Tian Q, et al. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nat Commun. 2020;11(1):5596. PMC7645772
• Bai X, et al. Glutamine metabolite alpha-ketoglutarate acts as an epigenetic co-factor to interfere with osteoclast differentiation. Bone. 2021;145:115855. PubMed 33383217
• Essential role of the metabolite alpha-ketoglutarate in bone tissue and bone-related diseases. PMC12368544
• Coudray-Lucas C, et al. Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients. Clin Nutr. 1999;18(5):307–311. PubMed 10601539
• Coudray-Lucas C, et al. A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients. J Nutr. 1998;128(3):563–569. PubMed 9482764
• Wirén M, Permert J. Alpha-ketoglutarate-supplemented enteral nutrition: effects on postoperative nitrogen balance and muscle catabolism. Nutrition. 2002;18(9):725–728. PubMed 12297206
• Riedel E, Nundel M, Hampl H. Alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism. Nephron. 1996;74(2):261–265. PubMed 8893139
• Jeppsson A, et al. Renal effects of alpha-ketoglutarate early after coronary operations. Ann Thorac Surg. 1998;65(3):684–690. PubMed 9527195
• Disrupted Alpha-Ketoglutarate Homeostasis: Understanding Kidney Diseases from the View of Metabolism and Beyond. PMC9248815
• Impact of Alpha-Ketoglutarate on Skeletal Muscle Health and Exercise Performance: A Narrative Review. Nutrients. 2024;16(22):3968
• Murgas Torrazza R, et al. Differential regulation of protein synthesis in skeletal muscle and liver of neonatal pigs by leucine through an mTORC1-dependent pathway. J Anim Sci Biotechnol. 2012;3(1):1. PMC3366465
• Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. PMC5753568
• α-Ketoglutarate Ameliorates Sarcopenia in D-Galactose-Induced Aging Mice by Modulating Protein Homeostasis and Optimizing Mitochondrial Function. PMC12608594
• α-Ketoisocaproic acid. Wikipedia
• Reactome: leu, ile, or val + alpha-ketoglutarate ⇌ BCKAs + glutamate [BCAT1]
• Ananieva EA, Wilkinson AC. The Critical Role of the Branched Chain Amino Acids Catabolism-Regulating Enzymes, BCAT and BCKD, in Human Pathophysiology. Int J Mol Sci. 2022;23(7):4022
• ClinicalTrials.gov NCT07114536: Evaluation of the Efficacy of Calcium α-Ketoglutarate (AKG-Ca) in Improving Human Aging